Literature DB >> 14990730

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Clare E Thomas1, Theresa A Storm, Zan Huang, Mark A Kay.   

Abstract

Transduction of the liver with single-stranded adeno-associated virus serotype 2 (AAV2) vectors is inefficient; less than 10% of hepatocytes are permissive for stable transduction, and transgene expression is characterized by a lag phase of up to 6 weeks. AAV2-based vector genomes packaged inside AAV6 or AAV8 capsids can transduce the liver with higher efficiency, but the molecular mechanisms underlying this phenomenon have not been determined. We now show that the primary barrier to transduction of the liver with vectors based on AAV2 capsids is uncoating of vector genomes in the nucleus. The majority of AAV2 genomes persist as encapsidated single-stranded molecules within the nucleus for as long as 6 weeks after vector administration. Double-stranded vector genomes packaged inside AAV2 capsids are at least 50-fold more active than single-stranded counterparts, but these vectors also exhibit a lag phase before maximal gene expression. Vector genomes packaged inside AAV6 or AAV8 capsids do not persist as encapsidated molecules and are more biologically active than vector genomes packaged inside AAV2 capsids. Our data suggest that the rate of uncoating of vector genomes determines the ability of complementary plus and minus single-stranded genomes to anneal together and convert to stable, biologically active double-stranded molecular forms.

Entities:  

Mesh:

Year:  2004        PMID: 14990730      PMCID: PMC353747          DOI: 10.1128/jvi.78.6.3110-3122.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.

Authors:  H Chao; Y Liu; J Rabinowitz; C Li; R J Samulski; C E Walsh
Journal:  Mol Ther       Date:  2000-12       Impact factor: 11.454

2.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.

Authors:  C H Miao; K Ohashi; G A Patijn; L Meuse; X Ye; A R Thompson; M A Kay
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

3.  Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  Nat Biotechnol       Date:  2000-05       Impact factor: 54.908

6.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.

Authors:  M Burton; H Nakai; P Colosi; J Cunningham; R Mitchell; L Couto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver.

Authors:  H Nakai; Y Iwaki; M A Kay; L B Couto
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.

Authors:  S Sanlioglu; P K Benson; J Yang; E M Atkinson; T Reynolds; J F Engelhardt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Authors:  J A Wagner; A H Messner; M L Moran; R Daifuku; K Kouyama; J K Desch; S Manley; A M Norbash; C K Conrad; S Friborg; T Reynolds; W B Guggino; R B Moss; B J Carter; J J Wine; T R Flotte; P Gardner
Journal:  Laryngoscope       Date:  1999-02       Impact factor: 3.325

10.  Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.

Authors:  C H Miao; H Nakai; A R Thompson; T A Storm; W Chiu; R O Snyder; M A Kay
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

View more
  154 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

3.  The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.

Authors:  Bassel Akache; Dirk Grimm; Kusum Pandey; Stephen R Yant; Hui Xu; Mark A Kay
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.

Authors:  Ziying Yan; Diana C M Lei-Butters; Xiaoming Liu; Yulong Zhang; Liang Zhang; Meihui Luo; Roman Zak; John F Engelhardt
Journal:  J Biol Chem       Date:  2006-08-09       Impact factor: 5.157

5.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 6.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

Review 7.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

Review 8.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

9.  Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.

Authors:  Chengwen Li; Matthew Hirsch; Aravind Asokan; Brian Zeithaml; Hong Ma; Tal Kafri; R Jude Samulski
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling.

Authors:  Prasad R Konkalmatt; Ronald J Beyers; Daniel M O'Connor; Yaqin Xu; Marc E Seaman; Brent A French
Journal:  Circ Cardiovasc Imaging       Date:  2013-03-27       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.